Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/06/2791711/0/en/Bioventus-Agrees-to-Nationwide-Contract-with-Aetna-Medicare-Advantage-Plans-for-DUROLANE-for-Knee-Osteoarthritis.html

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq:BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.

Read more at globenewswire.com

Related news for (BVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.